These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35171708)

  • 21. Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors.
    Lu S; Xie W; Zhang Y; Sun F; Huang J; Wang J; Zhu J; Zhen Z; Zhang Y
    Ann Oncol; 2023 Nov; 34(11):1065-1067. PubMed ID: 37666486
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson FH; Herbst RS
    Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract]   [Full Text] [Related]  

  • 24. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
    Ju G; Sun Y; Wang H; Zhang X; Mu Z; Sun D; Huang L; Lin R; Xing T; Cheng W; Liang J; Lin YS
    J Clin Endocrinol Metab; 2024 Jan; 109(2):505-515. PubMed ID: 37622214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
    Waguespack SG; Tewari SO; Busaidy NL; Zafereo ME
    JCO Precis Oncol; 2022 Apr; 6():e2100467. PubMed ID: 35420905
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
    Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
    Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Larotrectinib: First Global Approval.
    Scott LJ
    Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 31. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer.
    Leboulleux S; Lamartina L; Hadoux J; Baudin E; Schlumberger M
    Expert Opin Investig Drugs; 2022 Jul; 31(7):669-679. PubMed ID: 35522027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.
    Sherman EJ; Su YB; Lyall A; Schöder H; Fury MG; Ghossein RA; Haque S; Lisa D; Shaha AR; Tuttle RM; Pfister DG
    Thyroid; 2013 May; 23(5):593-9. PubMed ID: 23186033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
    Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer.
    Franco AT; Ricarte-Filho JC; Laetsch TW; Bauer AJ
    J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34523607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Larotrectinib: A Targeted Therapy for Solid Tumors.
    Mota-George G; Schneider SM
    Clin J Oncol Nurs; 2021 Apr; 25(2):181-187. PubMed ID: 33739345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
    Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
    Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 40. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.